plification after cessation of treatment with a drug that has a long half-life (5.5 months for bedaquiline).5

Margaretha de Vos, Ph.D.
Serej D. Ley, Ph.D.
Stellenbosch University
Cape Town, South Africa
margab@sun.ac.za

Helen Cox, Ph.D.
University of Cape Town
Cape Town, South Africa
and Others

Drs. de Vos and Ley and Drs. Warren and Cox contributed equally to this letter.

A complete list of authors is available with the full text of this letter at NEJM.org.

Use of trade names is for identification only and does not constitute endorsement by the Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this letter are those of the authors and do not necessarily repre...

Preventing Venous Thromboembolism in Patients with Cancer

TO THE EDITOR: Central venous catheters are commonly used for long periods in patients with cancer, and a nonnegligible increased risk of venous thromboembolism is associated with these devices.1 Nonetheless, the presence of a central venous catheter is not included as a component of established risk scores to determine which patients could benefit from thromboprophylaxis. We and others have reported on the role of anticoagulation (heparin or vitamin K antagonists) in reducing the risk of venous thromboembolism related to the use of a central venous catheter.1,2

Carrier et al. (Feb. 21 issue)3 report the results of the Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients (AVERT) trial, and, in the same issue of the Journal, Khorana et al.4 report the results of the CASSINI trial. These two pivotal trials evaluated factor Xa inhibitors for the prevention of venous thromboembolism in patients with cancer. The accompanying editorial by Agnelli5 elegantly merged the data from these trials, which showed a reduced risk of venous thromboembo...
No potential conflict of interest relevant to this letter was reported.


DOI: 10.1056/NEJMca1904003

DR. CARRIER AND COLLEAGUES REPLY: Stratification of ambulatory patients with cancer according to their underlying risk of venous thromboembolism is challenging. As highlighted by D’Ambrosio et al., known important risk factors may not be included in risk scores such as the Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism). For example, although central venous catheters may be associated with an increased risk of venous thromboembolism, 223 of the 574 patients (38.9%) who underwent randomization in the AVERT trial had a central venous catheter in place, and a proximal deep-vein thrombosis of the upper limbs developed in only 7 of these 223 patients (3.1%) over a period of 6 months.

The role of direct oral anticoagulants in preventing deep-vein thrombosis of the upper limbs is the subject of an ongoing pilot randomized trial assessing feasibility (ClinicalTrials.gov number, NCT03506815).1 Nonetheless, the Khorana score appears to be clinically relevant. Although approximately two thirds of the patients enrolled in our trial had a Khorana score of 2, the risk of a major venous thromboembolism was high in this subgroup: it occurred in 16 of 190 patients in the placebo group (8.4%) and in 6 of 186 patients in the apixaban group (3.2%) (risk difference, −5.2 percentage points; 95% confidence interval, −10.3 to −3.7).

Marc Carrier, M.D.
Gregoire Le Gal, M.D.
Philip S. Wells, M.D.
Ottawa Hospital Research Institute
Ottawa, ON, Canada
mcARRIER@toH.ca

Since publication of their article, the authors report no further potential conflict of interest.


DOI: 10.1056/NEJMca1904003

DR. KHORANA AND COLLEAGUES REPLY: D’Ambrosio and colleagues raise an important question regarding the risk of thrombosis in an upper limb among patients with central venous catheters. Prophylactic anticoagulation is not well established because of conflicting data and lower rates of thromboembolism reported in contemporary studies1 than in previous studies.2 A Khorana score of 3 or higher has been shown to be a risk factor for such events.3 In the CASSINI trial, which involved patients with a Khorana score of 2 or higher, 424 of 841 patients had a central venous catheter. Of these, 1 of 218 patients (0.5%) in the rivaroxaban group and 5 of 206 patients (2.4%) in the placebo group were adjudicated to have a deep-vein thrombosis in an upper limb while receiving the trial drug or placebo. In addition, excluding infectious complications, 2.8% of the patients in the rivaroxaban group and 4.9% in the placebo group had a catheter failure or other complications of a central venous catheter during the trial period. Our exploratory post hoc analysis suggests a reduced risk of thrombosis in an upper limb and noninfectious catheter failure with the use of daily rivaroxaban; these findings may be helpful in decision making regarding the use of thromboprophylaxis in outpatients with cancer.

Alok A. Khorana, M.D.
Cleveland Clinic
Cleveland, OH
khorana@ccf.org

Jodi Mones, M.D.
Gerald A. Soff, M.D.
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Mones reports receiving research support from Janssen to her institution. Since publication of his article, Dr. Soff reports receiving consulting fees from Bristol-Myers Squibb and Pfizer. No further potential conflict of interest relevant to this letter was reported.


DOI: 10.1056/NEJMca1904003